Sacituzumab tirumotecan (sac-TMT) as first-line treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Initial results from the phase II OptiTROP-Breast05 ...
Extreme E and Extreme H have announced a broadcast partnership with MBC Group, the MENA media company. The action begins in Qiddiya City, Saudi Arabia with Extreme E’s Final Lap on October 4th to 5th, ...
Phase I/Ib study of inavolisib (INAVO) alone and in combination with endocrine therapy ± palbociclib (PALBO) in patients (pts) with PIK3CA-mutated, hormone receptor–positive, HER2-negative locally ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results